Literature DB >> 28334430

Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: A prospective randomized trial.

Mingheng Liao1, Xiaofei Zhong2, Jingyi Zhang2, Yangyang Liu3, Zexin Zhu1, Hong Wu1, Yong Zeng1, Jiwei Huang1.   

Abstract

BACKGROUND AND OBJECTIVES: To compare 3-year clinical outcomes of radiofrequency ablation (RFA) targeting 5- or 10-mm margins for small hepatocellular carcinomas (HCCs) in cirrhotic patients.
METHODS: In total, 96 cirrhotic patients with a small solitary HCC (diameter ≤3 cm) were included in this prospective trial (ChiCTRTRC-10000954). Patients were stratified by Child-Pugh class and randomly allocated into groups targeting either wide margins (≥10 mm, WM) or narrow margins (≥5 mm but <10 mm, NM). RFA was performed under real-time monitoring, and ablative margins were evaluated by pre- and post-operative three-dimensional registration on CT.
RESULTS: The mean follow-up time was 38.3 ± 4.8 months, 83.3% (40/48) of patients succeeded in obtaining a 10-mm margin in WM group. Based on intention-to-treat analysis, the 3-year incidences of local tumor progression (LTP) (14.9% vs 30.2%), intrahepatic recurrence (IHR) (15.0% vs 32.7%), and recurrence-free survival (RFS) (31.7 ± 12.1 vs 24.0 ± 11.7 months) for WM group were significantly improved compared to NM group. Several prognostic factors were identified from univariate and multivariate analyses. Additionally, cirrhosis-stratified subgroup analyses demonstrated significant survival benefits of WM in patients with Child-Pugh class B cirrhosis.
CONCLUSIONS: RFA treatment targeting 10-mm margin may reduce the risk of tumor recurrence in cirrhotic patients with a single small HCC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  hepatocellular carcinoma; liver cirrhosis; margin; radiofrequency ablation; recurrence

Mesh:

Year:  2017        PMID: 28334430     DOI: 10.1002/jso.24607

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

Review 1.  Percutaneous Thermal Ablation for Hepatocellular Carcinoma.

Authors:  Jeffrey L Weinstein; Muneeb Ahmed
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 2.  Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum.

Authors:  Zlatko Devcic; Mohamed Elboraey; Lucas Vidal; Kabir Mody; Denise Harnois; Tushar Patel; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study.

Authors:  Yujing Xin; Xinyuan Zhang; Yi Yang; Yi Chen; Yanan Wang; Xiang Zhou; Xiao Li
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 4.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

5.  Comparative safety and effectiveness of ultrasound-guided radiofrequency ablation combined with preoperative three-dimensional reconstruction versus surgical resection for solitary hepatocellular carcinoma of 3-5 cm.

Authors:  Yuanfeng Gong; Yunqiang Tang; Yan Geng; Yu Zhou; Min Yu; Bowen Huang; Zhonghai Sun; Hui Tang; Zhixiang Jian; Baohua Hou
Journal:  J Cancer       Date:  2019-09-03       Impact factor: 4.207

6.  Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software.

Authors:  P Hendriks; W A Noortman; T R Baetens; A R van Erkel; C S P van Rijswijk; R W van der Meer; M J Coenraad; L F de Geus-Oei; C H Slump; M C Burgmans
Journal:  J Oncol       Date:  2019-09-19       Impact factor: 4.375

7.  Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Ernst Klotz; Hyunsik Woo; Mi Hye Yu; Ijin Joo; Eun Sun Lee; Joon Koo Han
Journal:  Korean J Radiol       Date:  2018-10-18       Impact factor: 3.500

Review 8.  Radiofrequency ablation in the management of primary hepatic and biliary tumors.

Authors:  Richard Hendriquez; Tara Keihanian; Jatinder Goyal; Rtika R Abraham; Rajnish Mishra; Mohit Girotra
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.